ADAMTS13 is a plasma metalloprotease that regulates the size of the von Willebrand factor (VWF) multimers. Genetic or acquired deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura (TTP) ...

A recombinant form of human ADAMTS13 approved for a different condition helped to save the life of a young mother with immune thrombotic thrombocytopenic purpura. A team led by investigators from ...

ADAMTS13 is a circulating zinc metalloprotease that cleaves the hemostatic glycoprotein von Willebrand factor (VWF) in a shear-dependent manner. Deficiency in ADAMTS13, owing to genetic mutations or ...

A transgenic mouse model is a proof-of-concept that platelet blood cells that are loaded with the enzyme ADAMTS13 can be an effective treatment in murine models of thrombotic thrombocytopenic purpura.

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...

A recombinant replacement for the ADAMTS13 protein (Adzynma) missing in congenital thrombotic thrombocytopenic purpura (TTP) restored levels and reduced acute TTP events, according to interim trial ...

Including biomarkers for non-ADAMTS13 in routine clinical testing could benefit diagnosis and follow-up in patients with immune-mediated thrombotic thrombocytopenic purpura (TTP). Patients with immune ...

A team led by investigators from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, used a new drug to save the life of a patient with immune thrombotic ...

Takeda’s recombinant ADAMTS13 (rADAMTS13) has been recommended by the European Medicines Agency’s human medicines committee to treat ADAMTS13 deficiency in children and adults with congenital ...

Immune thrombotic thrombocytopenic purpura, a rare blood clotting disorder, results from an autoimmune attack against an enzyme called ADAMTS13 A recombinant form of human ADAMTS13 approved for a ...

A team led by investigators from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, used a new drug to save the life of a patient with immune thrombotic ...